Silo Pharma Inc is a biotechnology company focused on leveraging psychedelic compounds and their therapeutic potential to treat various mental health conditions and neurological disorders. By researching and developing innovative drug delivery methods and formulations, the company aims to create effective treatments that can address unmet medical needs in the psychiatric space. Silo Pharma emphasizes collaboration with academic institutions and industry partners to advance its clinical programs and contribute to the evolving landscape of mental health therapies. Read More
NEW YORK - June 25th, 2025 - Silo Pharma, Inc. ( Nasdaq: SILO ) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.
SILO Pharma (NASDAQ: SILO) today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease.
Silo Pharma (NASDAQ: SILO) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its licensed patent application related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders. The patent, set to be issued as U.S. Patent No. 12,329,726 on June 17, 2025, bolsters Silo’s intellectual property around its lead candidate SPC-15, an intranasal PTSD treatment licensed from Columbia University. CEO Eric Weisblum emphasized the importance of this NIH-backed patent as the company prepares SPC-15 for Phase 1 clinical trials.
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”) that Silo licenses from Columbia University.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Silo Pharma (NASDAQ: SILO) announced a service agreement with Resyca BV to conduct a drug-device study on the microchip-enabled nasal spray system used in its lead PTSD treatment candidate, SPC-15. The study is intended to provide the final device data needed for an Investigational New Drug (IND) application to the FDA later this year. CEO Eric Weisblum noted the device’s ability to bypass the blood-brain barrier, potentially allowing faster and safer therapeutic delivery. Silo is also progressing two other SPC-15 studies, including a GLP-compliant toxicology study and a 7-day large animal safety trial requested by the FDA.
Silo Pharma (NASDAQ: SILO) a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed a public offering totaling approximately $2 million in gross proceeds. The offering included 3,333,338 shares of common stock or pre-funded warrants, along with Series A-1 and Series A-2 warrants, each allowing the purchase of up to 3,333,338 shares at $0.60 per share. The Series A-1 Warrants expire in five years, while the Series A-2 Warrants expire in eighteen months. H.C. Wainwright & Co. acted as the exclusive placement agent. Proceeds will be used for general working capital.
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire five years thereafter. The Series A-2 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire eighteen months thereafter.
Silo Pharma (NASDAQ: SILO) has priced a public offering of approximately 3.33 million shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants, all priced at $0.60 per unit. The Series A-1 and A-2 warrants are immediately exercisable at $0.60 per share, with expirations set at five years and eighteen months, respectively. Gross proceeds are expected to total roughly $2 million before fees and expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent, and proceeds will support general working capital.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
